TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ORMP

Oramed Pharmaceuticals Inc

Healthcare · Biotechnology

4.70$ +1.1% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Oramed Pharmaceuticals Inc (ORMP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 76.4% of the shares are freely tradable; institutional investors hold 37.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 37.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 17.8%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 76.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 3.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 42Mio.

Largest Shareholders

Institutions

Institutions ORMP
Name Stake (%) Shares Change (%) Date
Aquamarine Financial (Cayman) Ltd 6.04 2,512,175 +18.9 06/30/2026
Gem Investment Advisors, LLC 4.81 1,998,802 +21.9 06/30/2026
Mercer Global Advisors Inc. 4.59 1,910,540 +0.0 06/30/2026
Murchinson Ltd. 3.16 1,315,294 -1.9 03/31/2026
BML Capital Management LLC 2.08 866,269 -72.6 06/30/2026
BOOTHBAY FUND MANAGEMENT, LLC 1.44 600,716 -1.9 03/31/2026
Marshall Wace Asset Management Ltd 0.62 259,611 +0.2 03/31/2026

Funds

Funds ORMP
Name Stake (%) Shares Change (%) Date
iShares Russell 2000 ETF 1.50 625,040 -0.6 08/31/2026
Fidelity Small Cap Index 0.91 376,453 +0.0 06/30/2026
iShares Russell 2000 Value ETF 0.76 315,196 -0.2 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?